{"id":"https://openalex.org/W4200524724","doi":"https://doi.org/10.1016/j.euroneuro.2021.10.080","title":"P.0078 Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration","display_name":"P.0078 Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration","publication_year":2021,"publication_date":"2021-12-01","ids":{"openalex":"https://openalex.org/W4200524724","doi":"https://doi.org/10.1016/j.euroneuro.2021.10.080"},"language":"en","primary_location":{"id":"doi:10.1016/j.euroneuro.2021.10.080","doi":"https://doi.org/10.1016/j.euroneuro.2021.10.080","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.euroneuro.2021.10.080","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5036599898","display_name":"Miko\u0142aj Mat\u0142oka","orcid":"https://orcid.org/0000-0001-9891-1838","observed_orcids":["https://orcid.org/0000-0001-9891-1838"]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"M. Mat\u0142oka","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059915812","display_name":"Anna Gajos\u2010Draus","orcid":"https://orcid.org/0000-0001-6253-3329","observed_orcids":["https://orcid.org/0000-0001-6253-3329"]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"A. Gajos-Draus","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075102200","display_name":"I. Majkowska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"I. Majkowska","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008295994","display_name":"Sofiya Kokhanovska","orcid":"https://orcid.org/0000-0001-8682-2037","observed_orcids":["https://orcid.org/0000-0001-8682-2037"]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"S. Kokhanovska","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020386227","display_name":"Piotr Pankiewicz","orcid":"https://orcid.org/0000-0001-5566-8567","observed_orcids":["https://orcid.org/0000-0001-5566-8567"]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"P. Pankiewicz","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085668440","display_name":"Sylwia Janowska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"S. Janowska","raw_affiliation_strings":["Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018471269","display_name":"Kevin Wojcik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"K. Wojcik","raw_affiliation_strings":["Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074594600","display_name":"Maciej Wieczorek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"M. Wieczorek","raw_affiliation_strings":["Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Clinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5018257810","display_name":"Jerzy Pieczykolan","orcid":"https://orcid.org/0000-0002-5887-0952","observed_orcids":["https://orcid.org/0000-0002-5887-0952"]},"institutions":[{"id":"https://openalex.org/I4210096162","display_name":"Celon Pharma (Poland)","ror":"https://ror.org/00y35qw13","country_code":"PL","type":"company","lineage":["https://openalex.org/I4210096162"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"J. Pieczykolan","raw_affiliation_strings":["Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Celon Pharma SA, Preclinical Research Department, Kazun Nowy, Poland","institution_ids":["https://openalex.org/I4210096162"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210096162"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.21036381,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"53","issue":null,"first_page":"S55","last_page":"S56"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11337","display_name":"Tryptophan and brain disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2803","display_name":"Biological Psychiatry"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11921","display_name":"Electroconvulsive Therapy Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/esketamine","display_name":"esketamine","score":0.8389999866485596},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.8899999856948853},{"id":"https://openalex.org/keywords/antidepressant-effects","display_name":"antidepressant effects","score":0.7699999809265137},{"id":"https://openalex.org/keywords/rapid-antidepressant-response","display_name":"rapid antidepressant response","score":0.718999981880188},{"id":"https://openalex.org/keywords/psychotomimetic-effects","display_name":"psychotomimetic effects","score":0.9200000166893005},{"id":"https://openalex.org/keywords/pro-inflammatory-cytokines","display_name":"inflammatory cytokines","score":0.7720000147819519},{"id":"https://openalex.org/keywords/plasma-cytokine-levels","display_name":"plasma cytokines","score":0.9290000200271606},{"id":"https://openalex.org/keywords/montgomery-asberg-depression-rating-scale","display_name":"Montgomery-Asberg Depression Rating Scale","score":0.6840000152587891},{"id":"https://openalex.org/keywords/hamilton-depression-rating-scale","display_name":"Hamilton Depression Rating Scale","score":0.765999972820282}],"concepts":[{"id":"https://openalex.org/C2781065190","wikidata":"https://www.wikidata.org/wiki/Q7256512","display_name":"Psychotomimetic","level":4,"score":0.8750858306884766},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7457811832427979},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.7208298444747925},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.5944259762763977},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.5039333701133728},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.4994652271270752},{"id":"https://openalex.org/C2776466505","wikidata":"https://www.wikidata.org/wiki/Q385555","display_name":"Hamilton Rating Scale for Depression","level":4,"score":0.48343169689178467},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46928510069847107},{"id":"https://openalex.org/C2777342061","wikidata":"https://www.wikidata.org/wiki/Q7836891","display_name":"Treatment-resistant depression","level":4,"score":0.4530075788497925},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4276908040046692},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.41262978315353394},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3850864768028259},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.24906465411186218},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2781161787","wikidata":"https://www.wikidata.org/wiki/Q48360","display_name":"Hippocampus","level":2,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.euroneuro.2021.10.080","doi":"https://doi.org/10.1016/j.euroneuro.2021.10.080","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.euroneuro.2021.10.080","pdf_url":null,"source":{"id":"https://openalex.org/S168041952","display_name":"European Neuropsychopharmacology","issn_l":"0924-977X","issn":["0924-977X","1873-7862"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Neuropsychopharmacology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G2404192326","display_name":null,"funder_award_id":"POIR 1/1.1.1","funder_id":"https://openalex.org/F4320335039","funder_display_name":"Narodowe Centrum Bada\u0144 i Rozwoju"}],"funders":[{"id":"https://openalex.org/F4320335039","display_name":"Narodowe Centrum Bada\u0144 i Rozwoju","ror":"https://ror.org/05pwfyy15"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W2023081218","https://openalex.org/W2525236957","https://openalex.org/W2730275538","https://openalex.org/W2888191993"],"related_works":["https://openalex.org/W2121117021","https://openalex.org/W4200302445","https://openalex.org/W2022994360","https://openalex.org/W2138494388","https://openalex.org/W2128918664","https://openalex.org/W2587748623","https://openalex.org/W2797951242","https://openalex.org/W2109334244","https://openalex.org/W2800815779","https://openalex.org/W2913479851"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-12-31T00:00:00"}